Is semaglutide still on the FDA drug shortage list?
Is semaglutide still on the FDA shortage list?
No. As of Nov 15, 2026, FDA’s drug shortage data, read through openFDA, lists no semaglutide product with status “Current.” Its only semaglutide entries are 3 semaglutide tablet presentations with status “To Be Discontinued,” posted Jun 4, 2026, which is FDA’s notice of a product being discontinued, not a shortage. FDA’s Drug Shortages Database page for Semaglutide Injection shows the status “Resolved.” FDA determined the semaglutide injection shortage resolved on Feb 21, 2025, after first listing it on Mar 31, 2022.
Checked Nov 15, 2026 against FDA’s drug shortage data through openFDA, and Nov 15, 2026 against FDA’s Drug Shortages Database page for Semaglutide Injection. Shortage status can change; FDA’s database is the current word.
Semaglutide on FDA’s shortage list, by date
| FDA’s words or record | Source | ||
|---|---|---|---|
| Mar 31, 2022 | Listed | “Wegovy was approved by FDA in June 2021 (NDA 215256) and added to FDA’s drug shortage list on March 31, 2022.” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Aug 23, 2022 | Listed | “Ozempic was approved by FDA in December 2017 (NDA 209637) and added to FDA’s drug shortage list on August 23, 2022.” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Feb 21, 2025 | Resolved | “FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Semaglutide injection products have been in shortage since 2022 due to increased demand.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Apr 22, 2025 | 503A grace period end | “For state-licensed pharmacists or physicians compounding under section 503A of the FD&C Act, 60 calendar days from the date of this order, until April 22, 2025” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Apr 24, 2025 | Litigation | “On April 24, 2025, the district court denied the plaintiffs’ preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.) regarding compounded semaglutide.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| May 22, 2025 | 503B grace period end | “For outsourcing facilities under section 503B of the FD&C Act, 90 calendar days from the date of this order, until May 22, 2025.” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Apr 1, 2026 | Status statement | “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Jun 4, 2026 | To Be Discontinued | FDA’s shortage data posts Semaglutide Tablet (Rybelsus) with status “To Be Discontinued,” first posted Jun 4, 2026: 3 presentations. | FDA drug shortage data, via openFDA drug shortages endpoint |
FDA’s most recent statement
- Apr 1, 2026: FDA stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list. FDA explained that outsourcing facilities may compound from bulk drug substances only if the substance is on the 503B bulks list or the drug is on the shortage list at the time of compounding, distribution and dispensing. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
What the end of the shortage meant for compounding
FDA set dates after which it would act on compounding that depended on semaglutide being in shortage: April 22, 2025 for state-licensed pharmacies and physicians (section 503A) and May 22, 2025 for outsourcing facilities (section 503B). The rules FDA states now are on Is compounded semaglutide still legal?. All GLP-1 drugs: shortage history.
Common questions
When was semaglutide added to the shortage list?
FDA’s February 21, 2025 order says Wegovy was added on March 31, 2022 and Ozempic on August 23, 2022.
When did FDA say the semaglutide shortage was resolved?
February 21, 2025.
Sources
- FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy)
- FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound)
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA drug shortage data, via openFDA drug shortages endpoint
- FDA Drug Shortages (via openFDA drug shortages endpoint)
- FDA Drug Shortages Database: Semaglutide Injection
Records last pulled Nov 15, 2026. Every entry links to the original public record.